Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst

Key Points

• Brookline Capital slightly raised its Q2 2026 EPS estimate for CRISPR to ($1.16) from ($1.22) and now models FY2026 EPS of ($4.96) and FY2027 EPS of ($5.51), while the street consensus remains a “Hold” with an average target of $64.24.
• CRISPR recently missed its quarterly results, reporting EPS of ($1.37) vs. ($1.15) expected and revenue of $0.86M (down 97.8% year‑over‑year), highlighting ongoing negative margins and operating challenges.
• The company priced an upsized $550M convertible senior notes offering to extend runway (but potentially dilutive), and insiders including the CEO and general counsel sold shares this week—moves that could weigh on near‑term investor sentiment.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Brookline Capital Acquisition lifted their Q2 2026 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, March 11th. Brookline Capital Acquisition analyst L. Cann now forecasts that the company will post earnings of ($1.16) per share for the quarter, up from their previous forecast of ($1.22). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Brookline Capital Acquisition also issued estimates for CRISPR Therapeutics' Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.31) EPS, FY2026 earnings at ($4.96) EPS and FY2027 earnings at ($5.51) EPS.

Other analysts have also recently issued reports about the company. Bank of America cut their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a "buy" rating on the stock in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Chardan Capital boosted their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a "buy" rating in a research report on Saturday, February 14th. Evercore reaffirmed an "outperform" rating and issued a $74.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Finally, Citizens Jmp dropped their price target on CRISPR Therapeutics from $86.00 to $80.00 and set a "market outperform" rating on the stock in a research note on Friday, January 30th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Hold" and an average target price of $64.24.

CRISPR Therapeutics Trading Down 2.1%

Shares of NASDAQ CRSP opened at $48.87 on Friday. The company's 50-day moving average price is $54.20 and its 200 day moving average price is $57.28. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $78.48. The stock has a market cap of $4.69 billion, a price-to-earnings ratio of -7.50 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company's revenue for the quarter was down 97.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.01) EPS.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently modified their holdings of CRSP. GSK plc acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at approximately $168,890,000. Orbis Allan Gray Ltd increased its stake in CRISPR Therapeutics by 76.9% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company's stock valued at $134,467,000 after buying an additional 1,201,600 shares during the period. Geode Capital Management LLC grew its stake in shares of CRISPR Therapeutics by 98.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company's stock worth $100,789,000 after purchasing an additional 1,025,979 shares during the last quarter. SR One Capital Management LP grew its position in shares of CRISPR Therapeutics by 94.4% during the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company's stock worth $132,132,000 after buying an additional 989,812 shares during the period. Finally, State Street Corp raised its holdings in shares of CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company's stock valued at $159,082,000 after purchasing an additional 859,334 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,798 shares of the business's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total value of $517,334.40. Following the completion of the transaction, the chief executive officer directly owned 235,558 shares in the company, valued at approximately $12,437,462.40. The trade was a 3.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,800 shares of the firm's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total value of $147,840.00. Following the completion of the sale, the general counsel directly owned 87,815 shares of the company's stock, valued at $4,636,632. The trade was a 3.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 111,677 shares of company stock valued at $6,308,848 over the last 90 days. Corporate insiders own 4.30% of the company's stock.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY2025 commercial progress — CASGEVY generated meaningful revenue ($116M for FY25, $54M in Q4), showing commercial traction that supports long-term upside. Article Title
• Positive Sentiment: Analyst small upgrades — Brookline slightly raised Q2 2026 and FY2026 EPS forecasts (Q2 to -$1.16; FY2026 to -$4.96) and modestly raised FY2027, a sign one sell-side shop sees marginally better near-term results (still negative EPS).
• Neutral Sentiment: High-profile trading headlines — reports that ARK Invest was buying CRSP while the stock moved sharply have drawn attention and increased volatility; buying by a marquee investor can support sentiment but also coincides with short-term swings. Article Title
• Neutral Sentiment: Short-interest reporting appears anomalous/blank in recent feeds (zeros/NaN), so retail/quant signals from short data are unclear and likely not driving a clear directional signal.
• Negative Sentiment: $550M convertible senior notes offering — CRISPR priced an upsized $550M convertible debt offering due 2031. This raises cash (runway) but creates potential share dilution if converted and tends to weigh on equity sentiment near-term. Article Title
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni sold ~9,798 shares and General Counsel James Kasinger sold ~2,800 shares at ~$52.80. Insider sales can be interpreted negatively by some investors even if for personal liquidity; filings: CEO SEC Filing and GC SEC Filing
• Negative Sentiment: Mixed-to-lower estimate tweaks for some quarters and out years — Brookline trimmed Q3/Q4 2026 and reduced FY2028–FY2030 estimates slightly, signaling continued uncertainty around timing of profitability and long-term modeling.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.